Fig. 5From: An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimodChanges of the number of myofibroblasts in skin biopsies from each individual patient treated with paquinimod. The myofibroblasts were analyzed by immunohistochemistry and detected by using an antibody recognizing α-smooth muscle actin (αSMA) in skin biopsies taken at baseline and week 8. The mean (shown in red) reduction was 8% (p = 0.023)Back to article page